- Walgreens Boots forecasts 2025 adjusted earnings per share (EPS) between $1.40 and $1.80, with an estimate of $1.73.
- Projected sales for 2025 are between $147 billion and $151 billion, slightly above the estimate of $146.9 billion.
- Adjusted operating income for 2025 is expected between $1.6 billion and $2.0 billion, with an estimate of $1.89 billion.
- For the fourth quarter, adjusted EPS was 39 cents, down from 67 cents year-over-year, but above the estimate of 36 cents.
- International sales reached $5.97 billion, a 3.2% increase year-over-year, surpassing the estimate of $5.84 billion.
- Total quarterly sales were $37.55 billion, marking a 6% year-over-year growth and exceeding the estimate of $35.56 billion.
- The adjusted gross margin for the quarter was 16.9%, down from 18.6% year-over-year, and below the estimate of 17.6%.
- US Retail Pharmacy sales totaled $29.47 billion, a 6.5% year-over-year increase, beating the estimate of $27.48 billion.
- US Healthcare sales were $2.11 billion, growing 7.2% year-over-year but slightly below the estimate of $2.15 billion.
- Adjusted gross profit for the quarter was $6.33 billion, a 4% decrease year-over-year, but ahead of the estimate of $6.24 billion.
- Adjusted operating income for the quarter was $424 million, reflecting a 38% year-over-year drop, yet above the estimate of $396 million.
Walgreens Boots Alliance on Smartkarma
Analysts on Smartkarma, such as Baptista Research, are closely following Walgreens Boots Alliance and recently published a bullish research report titled “Walgreens Boots Alliance: Enhancing Digital & Operational Efficiency To Expand Margins! – Major Drivers”. The report delves into the company’s third-quarter performance for Fiscal Year 2024, highlighting both positive developments and drawbacks across its business segments.
The analysis focuses on Walgreens Boots Alliance‘s efforts to improve digital operations and operational efficiency to drive margin expansion. Investors can gain valuable insights from research reports on Smartkarma by analysts like Baptista Research to better understand the factors influencing the company’s performance and make informed investment decisions.
A look at Walgreens Boots Alliance Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Walgreens Boots Alliance is positioned well for long-term success in terms of value and dividend payouts with top scores in both categories. This indicates strong fundamentals and attractiveness for investors seeking stable returns. However, the company lags in growth, resilience, and momentum scores, suggesting potential challenges in these areas. Despite this, the company’s core focus on providing a wide range of healthcare products and services, including health services and wellness programs, enhances its overall market position.
Walgreens Boots Alliance, Inc., known for operating retail drugstores offering a mix of prescription drugs, general goods, and a range of health services, continues to strengthen its value proposition for investors. With a focus on providing essential healthcare products and services, the company’s high scores in value and dividend highlight its stability and income potential. While facing some growth and resilience challenges, its commitment to health and wellness services underscores its long-term relevance in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
